RGEN - レプリジェン （Repligen Corporation）RGENのニュース
Equities Analysts Offer Predictions for Repligen Co.’s Q3 2022 Earnings (NASDAQ:RGEN) 2022/08/05 05:31:24 ForexTV
Equities research analysts at William Blair reduced their Q3 2022 earnings per share (EPS) estimates for Repligen in a report issued on Tuesday, August 2nd. William Blair analyst J. Kreger now … Read Full Story at source (may require registration) The post Equities Analysts Offer Predictions for Repligen Co.’s Q3 2022 Earnings (NASDAQ:RGEN) appeared first on ForexTV .
Why Shares of Repligen Surged This Week 2022/08/04 17:57:03 The Motley Fool
The bioprocessing equipment company is seeing growth prospects accelerate for its non-COVID-related revenue.
Repligen PT Raised to $275 at Stephens 2022/08/03 10:53:05 Investing.com
https://www.investing.com/news/pro/repligen-pt-raised-to-275-at-stephens-432SI-2861705
Indexes Obscure Strong Surges in Some Stocks 2022/08/02 20:39:38 The Street RealMoney
Names like ZoomInfo, Repligen and Uber bounce higher, despite down Dow and drama over Taiwan.
Why Repligen Corporation Stock Is Storming Higher Today 2022/08/02 18:56:00 The Motley Fool
Repligen''s strong second-quarter results are a hit with investors.
2021-2027 Tangential Flow Filtration Market Trending Technologies, Remarkable Developments and Key Players like GE, Merck, Sartorius, Repligen, Parker Hannifin, Sterlitech, Bionet 2021/09/27 11:07:47 OpenPR
Overview of Global Tangential Flow Filtration Market: The universal Tangential Flow Filtration Market report gives us an in-depth overview of the research trends for the financial year 2021. The base year for calculation in the report is taken as 2020 while
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs 2021/09/22 11:45:28 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (NASDAQ: XLRN ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Corvus Pharmaceuticals, Inc. NASDAQ: CRVS) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) IVERIC bio, Inc. (NASDAQ: ISEE ) Leap Therapeutics, Inc. (NASDAQ: LPTX ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 20) Ambrx Biopharma Inc. (NYSE: AMAM ) Absci Corporation (NASDAQ: ABSI ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aytu Biopharma, Inc. (NASDAQ: AYTU ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) Biomea Fusion, Inc. (NASDAQ: BMEA ) Centessa Pharmaceuticals Limited (NASDAQ: CNTA ) Codex DNA, Inc. (NASDAQ: DNAY ) Emergent BioSolutions Inc. (NYSE: EBS ) Galapagos NV (NASDAQ: GLPG ) Harpoon Therapeutics, Inc.
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study 2021/09/16 11:48:49 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACHL ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aditxt, Inc. (NASDAQ: ADTX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Ardelyx, Inc. (NASDAQ: ARDX ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) CVRx, Inc. (NASDAQ: CVRX ) Dermata Therapeutics, Inc.
Repligen Announces Agreement to Acquire Avitide Inc. 2021/09/16 11:40:00 Intrado Digital Media
WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines.
2021-2027 Tangential Flow Filtration Market Trending Technologies, Remarkable Developments and Key Players like GE, Merck, Sartorius, Repligen, Parker Hannifin, Sterlitech, Bionet 2021/09/27 11:07:47 OpenPR
Overview of Global Tangential Flow Filtration Market: The universal Tangential Flow Filtration Market report gives us an in-depth overview of the research trends for the financial year 2021. The base year for calculation in the report is taken as 2020 while
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs 2021/09/22 11:45:28 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (NASDAQ: XLRN ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Corvus Pharmaceuticals, Inc. NASDAQ: CRVS) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) IVERIC bio, Inc. (NASDAQ: ISEE ) Leap Therapeutics, Inc. (NASDAQ: LPTX ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 20) Ambrx Biopharma Inc. (NYSE: AMAM ) Absci Corporation (NASDAQ: ABSI ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aytu Biopharma, Inc. (NASDAQ: AYTU ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) Biomea Fusion, Inc. (NASDAQ: BMEA ) Centessa Pharmaceuticals Limited (NASDAQ: CNTA ) Codex DNA, Inc. (NASDAQ: DNAY ) Emergent BioSolutions Inc. (NYSE: EBS ) Galapagos NV (NASDAQ: GLPG ) Harpoon Therapeutics, Inc.
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study 2021/09/16 11:48:49 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACHL ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aditxt, Inc. (NASDAQ: ADTX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Ardelyx, Inc. (NASDAQ: ARDX ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) CVRx, Inc. (NASDAQ: CVRX ) Dermata Therapeutics, Inc.
Repligen Announces Agreement to Acquire Avitide Inc. 2021/09/16 11:40:00 Intrado Digital Media
WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines.